Ocular Therapeutix (OCUL) Stock Dropped, So What Is Driving Attention Now?

Ocular Therapeutix (OCUL) is back in focus after Chief Strategy Officer Sanjay Nayak resigned on October 16, 2026, to become chief executive of a privately held company, drawing renewed attention to the biotech’s leadership bench.

Recent trading has been rough for Ocular Therapeutix, with the share price down 8.44% over the last day and 37.04% over 30 days, while the one year total shareholder return has declined 48.36%. However, the three year total shareholder return is still up roughly 171%, indicating that long term holders are sitting on sizeable historical gains even as near term momentum fades and the latest leadership change adds another layer of perceived execution risk to price moves.

Pace the pressure around Ocular Therapeutix by scanning hand-picked small caps that pair medical science with stronger recent momentum using the 33 healthcare AI stocks.

After a sharp pullback and a fresh question mark over its leadership team, Ocular Therapeutix now sits at a level where investors have to decide whether most of the upside is already in the rearview mirror or still ahead, which turns the spotlight squarely onto valuation.

Most Popular Narrative: 77% Undervalued

Analysts following Ocular Therapeutix see a large gap between their fair value estimate of about $27.09 and the latest close at $6.29, which puts the whole debate around the stock onto whether Axpaxli can eventually support those richer assumptions.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6 to 12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

See why 11 investors see Ocular Therapeutix as 77% undervalued.

Result: Fair Value of $27.09 (UNDERVALUED)

Still, Ocular Therapeutix faces real pressure if Axpaxli stumbles in key trials or if higher spending and funding needs dilute existing shareholders.

Find out about the key risks to this Ocular Therapeutix narrative.

Another View: Pricing Risk Around Ocular Therapeutix

On the flip side of the SWS DCF model that points to Ocular Therapeutix trading well below an estimated future cash flow value of $112.16, the current P/S ratio of 26.5x is far higher than the US pharmaceuticals average of 4.3x and the fair ratio of 0.1x. This hints at meaningful downside valuation risk if sentiment shifts back toward those lower multiples. Which lens do you trust more when the story is this dependent on AXPAXLI actually delivering?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

Mixed messages on Ocular Therapeutix so far and still unsure what to make of it. Act while the information is fresh, and pressure test the upside and downside by checking the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Ocular Therapeutix?

If Ocular Therapeutix has your attention but your portfolio needs more than one story, broaden your opportunity set with a few focused stock ideas.

• Target potential bargains supported by stronger fundamentals by scanning a curated pool of 35 high quality undervalued stocks that already show healthier cash generation and balance sheets.
• Strengthen your income stream by reviewing 8 dividend fortresses that combine higher yields with an emphasis on durability rather than short term payout spikes.
• Dial back volatility risk by filtering for 32 resilient stocks with low risk scores where financial resilience and lower risk scores take priority over fast but fragile growth stories.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com